While several methodologies applied against several hotspot PIK3CA mutations, no additional TCRs against p.N345K, p.E545K or other hotspot PIK3CA neoepitopes were identified, indicating that reactivity against these candidate neoepitopes was not prevalent in this group of patients with metastatic cancer (Table S3). Here, PIK3CA is linked to metastatic malignant neoplasm.